FDA warns of fake Teva ADHD drug as shortage continues
The FDA has warned patients about counterfeit versions of a Teva ADHD drug that is on the drug shortage list.
Teva will try to use different delivery devices for biosimilars to gain an edge over innovator products, its North American CEO said.
The MHRA has suspended the license for a Teva generic over suggestions its dissolution rate could affect interchangeability.
Production quality control issues drag on Teva Q1 sales
Quality issues slowed first quarter revenue growth at Teva but, with one plant resuming shipping and another awaiting re-inspection, sales are expected to pick up.
Teva resumes production at Irvine, CA facility
Teva has resumed production at its Irvine, California plant a year after quality control issues put production on hold.
Appointments at Teva, Codexis, Albemarle and BayBio – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Teva, Codexis, Albemarle and BayBio.
Teva collaborates to save failed drugs
Teva plans to acquire oncology drugs that fail late-stage clinical trials and collaborate with Optimata to "efficiently rescue" the therapeutics and gain regulatory approval.
Teva asks ICG to help its control “indirect spend”
The US subsidiary of world leading generics firm Teva Pharmaceutical Industries has called in procurement specialist ICG Commerce to help it cut its outsourcing spend as part of ongoing cost reduction operations.
Pliva axing 790 employees; still looks to grow
Pliva is laying off 790 employees over the next 12 months following its acquisition by Teva but still intends to significantly increase API and finished product output over this period.
Teva and Lonza JV targets biosimilars
Teva has made a big push into the biosimilars market through a joint venture with Lonza, which will give the generics giant expertise in biologics manufacture.
Watson to buy Teva drugs for $36m
Watson Pharmaceuticals has paid Israeli generics firm Teva $36m (€27.6m) for 17 products that the latter firm is selling under the terms of its $7.5bn acquisition of Barr Pharmaceuticals.
Teva Kowa JV to target Japanese generics market
Teva and Kowa have set their sights on Japan’s $4.6bn (€3.1bn) generics market with their development and manufacturing joint venture Teva-Kowa Pharma.
Teva pounces on Barr with $7.5bn offer
There looks set to be further consolidation in the generics sector with Teva offering to acquire Barr Pharmaceuticals in a deal worth $7.5bn
Strong sales at Teva's API division
Teva's sales of active pharmaceutical ingredients (APIs) for the
first quarter of 2008 rose by 51 per cent on the previous years
figure, taking to total to $510m.
Teva to invest $100m in Hungary
Israeli generics maker Teva will spend $100m to double its
manufacturing capacity in Hungary, as the pharma global spread